Premium
Fosinopril Prevents the Development of Tactile Allodynia in a Streptozotocin‐Induced Diabetic Rat Model
Author(s) -
AraizaSaldaña Claudia Ivonne,
PedrazaPriego Erick Fabián,
TorresLópez Jorge Elías,
RochaGonzález Héctor Isaac,
CastañedaCorral Gabriela,
HongChong Enrique,
GranadosSoto Vinicio
Publication year - 2015
Publication title -
drug development research
Language(s) - English
Resource type - Journals
SCImago Journal Rank - 0.582
H-Index - 60
eISSN - 1098-2299
pISSN - 0272-4391
DOI - 10.1002/ddr.21280
Subject(s) - streptozotocin , fosinopril , medicine , diabetes mellitus , endocrinology , blood pressure , angiotensin converting enzyme
Preclinical ResearchThe aim of this study was to evaluate fosinopril‐induced changes in hemodynamic parameters and tactile allodynia in a rat model of diabetes. Diabetes was induced by streptozotocin (STZ; 50 mg/kg, i.p.) in male Wistar rats. STZ produced hyperglycemia, weight loss, polydipsia, polyphagia, and polyuria as well as long‐term arterial hypotension, bradycardia, and tactile allodynia at 10–12 weeks. Daily administration of the angiotensin converting enzyme inhibitor, fosinopril (25 mg/kg, p.o., for 11 weeks) partially reduced the loss of body weight, decreased hyperglycemia, and systolic blood pressure in diabetic rats. Likewise, systemic administration of fosinopril prevented the development and maintenance of tactile allodynia in STZ‐induced diabetic rats. These data suggest that fosinopril may have a role in the pharmacotherapy of diabetic neuropathic pain. Drug Dev Res 76 : 442–449, 2015. © 2015 Wiley Periodicals, Inc.